Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA drug delivery workshop

This article was originally published in The Gray Sheet

Executive Summary

Event is slated for later this summer, "with the idea that we know that when there's a guidance written...you've got almost twice the chance of getting the first cycle of approval...than you do with no guidance written," CDRH Director David Feigal remarks at AdvaMed annual meeting March 22 in Aventura, Fla. The workshop is part of a agency-wide initiative to improve problematic regulatory paths (1"The Gray Sheet" March 24, 2003, p. 11)...
Advertisement

Related Content

CDRH Problematic Regulatory Paths Review On Near-Term Agenda – Feigal
CDRH Problematic Regulatory Paths Review On Near-Term Agenda – Feigal
Advertisement
UsernamePublicRestriction

Register

MT018113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel